IASLC Update on Classification of Pulmonary Neuroendocrine Neoplasms

Since the publication of the 2021 WHO classification of thoracic tumors, our knowledge of pulmonary neuroendocrine neoplasms (NENs) has expanded significantly, particularly through the elucidation of molecular pathways and proposals to refine histopathologic classification. This expanded knowledge across all aspects of pulmonary NENs holds promise for more precise stratification of neuroendocrine tumors (NETs) and the potential development of novel, subtype-specific therapeutic strategies for all NENs. Based on our comprehensive review of the current pulmonary NEN landscape, our multidisciplinary expert panel has deliberated on the modification and updating of the 2021 classification, resulting in the proposal of a new pulmonary carcinoid/NET classification presented in this position paper, which incorporates the following three major points: (1) The proposed framework continues the shift from the traditional carcinoid terminology toward broader adoption of the “NET” nomenclature as found in other organ systems while retaining the term “carcinoid” as the primary diagnostic term to ensure clear communication with thoracic clinical providers. (2) Ki-67 has been incorporated as a diagnostic criterion, aligning with practices in other NET classifications. (3) There is formal recognition of the concept of “carcinoid/NET G3,” a rare subset of lung carcinoids characterized by increased proliferative activity but with molecular features more aligned with pulmonary NETs than with high-grade neuroendocrine carcinomas. This position paper on the current knowledge of pulmonary NENs, including the proposed carcinoid/NET classification, will aid in accurate tumor categorization and guide treatment strategies.